Friday, Philip Morris International(PM) presented scientific evidence to the U.S. Food and Drug Administration's (FDA) Tobacco Products Scientific Advisory Committee.
This was part of the agency's review of a Modified Risk Tobacco Product designation for PM's ZYN nicotine pouches. If granted, this designation would allow PM's U.S. businesses to inform legal-age adult smokers that switching completely from cigarettes to ZYN significantly lowers the risk of several smoking-related diseases.
According to PM, the FDA noted that the proposed reduced-risk claim is scientifically accurate, while youth nicotine pouch use remains relatively low.
The company also stated that the evidence showed ZYN contains substantially fewer harmful chemicals than cigarettes and supports complete switching among adult smokers.
PM is currently trading at $170.44, down $0.39 or 0.23 on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.